- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02625506
Efficacy of Tramadol With Levobupivacaine for Modified Pectoral Nerve Block
Efficacy of Adding Tramadol as Adjunctive Analgesic With Levobupivacaine in Modified Pectoral Nerve Block for Modified Radical Mastectomy Surgery
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Breast surgeries are usually associated with sever postoperative pain ,good perioperative analgesic technique after breast surgery is always questionable Thoracic epidural and paravertebral blocks became the gold standard techniques for pain relief, however they may be associated with complications such as spinal cord injury, total spinal anesthesia ,inadvertent intravascular injection and pneumothorax.
Pecs block is less invasive procedure involving ultrasound guided inter-fascial injections which has been suggested as potential alternative analgesic technique.
The block produces excellent analgesia and can be used as a rescue block in cases where the analgesia provided by the paravertebral or epidural was patchy or ineffective .
Different drugs, including opioids, non-steroidal anti-inflammatory drugs, ketamine, clonidine, and neostigmine, have been added to local anesthetics to improve the duration and quality of analgesia.Tramadol has also been used for pain management of patients.
The power of this clinical trial was prospectively calculated using the G Power analysis program. Using a priory power analysis with accuracy mode calculations with visual analogue score (VAS) as the primary variant and assuming type I error protection of 0.05 and an effect size convention of 0.9, a total sample size of 54 patients (27 patients in each group) produced a power of 0.90. To protect against drop out cases we added 6 cases to the total number (total of 60 cases)
Study Type
Enrollment (Actual)
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
DK
-
Mansoura, DK, Egypt, 050
- Mansoura University, Mansoura Oncology Center
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- American Society of Anesthesiologists physical status I or II.
- Patients scheduled for radical mastectomy surgery.
Exclusion Criteria:
- Severe or uncompensated cardiovascular diseases
- renal diseases
- Hepatic diseases
- Endocrinal diseases.
- Pregnancy
- Postpartum
- Lactating females
- Allergy to study medications.
- Local skin infection
- Bleeding disorder
- Coagulation abnormality
- Spine deformity
- chest deformity
- Psychiatric disease
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Supportive Care
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Quadruple
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Placebo Comparator: Levobupivacaine
Patients will be subjected for radical mastectomy surgery and pectoral nerve block with levobupivacaine
|
Ultrasound guided Pecs block will be performed using 20 ml of levobupivacaine
|
Active Comparator: Levobupivacaine and Tramadol
Patients will be subjected for radical mastectomy surgery and pectoral nerve block with levobupivacaine and tramadol
|
Ultrasound guided Pecs block will be performed using 20 ml of levobupivacaine in conjunction with tramadol
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Postoperative pain
Time Frame: For the first 24 hours after surgery
|
Postoperative pain will be assessed by utilizing visual analogue scale (VAS)
|
For the first 24 hours after surgery
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Changes in heart rate
Time Frame: For one hour after surgery
|
For one hour after surgery
|
Changes in blood pressure
Time Frame: For one hour after surgery
|
For one hour after surgery
|
Changes in peripheral oxygen saturation
Time Frame: For one hour after surgery
|
For one hour after surgery
|
Changes in end-tidal carbon dioxide tension
Time Frame: For one hour after surgery
|
For one hour after surgery
|
Time for first analgesic request from extubation
Time Frame: for 24 hours after surgery
|
for 24 hours after surgery
|
Total analgesics received for 24 hrs after surgery
Time Frame: for 24 hours after surgery
|
for 24 hours after surgery
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Salwa MS Hayes, MD, assistant professor of Anesthesia and Surgical Intensive Care
- Study Director: Reem A Sharkawy, MD, Lecture of Anesthesia and Surgical Intensive Care
- Study Chair: Tamer EM Farahat, MD, Lecture of Anesthesia and Surgical Intensive Care
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- R/15.05.67
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Breast Cancer
-
Northwestern UniversityEisai Inc.UnknownMale Breast Cancer | Stage II Breast Cancer | Stage IIIA Breast Cancer | Stage IIIB Breast Cancer | Triple-negative Breast Cancer | Stage IA Breast Cancer | Stage IB Breast Cancer | Stage IIIC Breast Cancer | Estrogen Receptor-negative Breast Cancer | Progesterone Receptor-negative Breast Cancer | HER2-negative...United States
-
Rutgers, The State University of New JerseyNational Cancer Institute (NCI); Rutgers Cancer Institute of New JerseyActive, not recruitingStage IIIA Breast Cancer | Stage IIIB Breast Cancer | Triple-negative Breast Cancer | Stage IIA Breast Cancer | Stage IIB Breast Cancer | Stage IIIC Breast Cancer | Estrogen Receptor-negative Breast Cancer | Progesterone Receptor-negative Breast Cancer | HER2-negative Breast CancerUnited States
-
University of Southern CaliforniaNational Cancer Institute (NCI)TerminatedMale Breast Cancer | Stage IV Breast Cancer | Stage II Breast Cancer | Stage IIIA Breast Cancer | Stage IIIB Breast Cancer | Stage IA Breast Cancer | Stage IB Breast Cancer | Stage IIIC Breast Cancer | Recurrent Breast CancerUnited States
-
Baylor Breast Care CenterRecruitingBreast Cancer | Breast Neoplasm | Triple Negative Breast Cancer | Triple Negative Breast Neoplasms | HER2-positive Breast Cancer | Breast Cancer Stage II | Breast Cancer Female | Breast Cancer Stage III | Estrogen Receptor-positive Breast Cancer | Hormone Receptor-positive Breast Cancer | Breast Cancer InvasiveUnited States
-
Innocrin PharmaceuticalCompletedBreast Cancer | Advanced Breast Cancer | Metastatic Breast Cancer | Triple Negative Breast Cancer | Male Breast Cancer | ER+ Breast Cancer | Cancer of the BreastUnited States
-
University of WashingtonTerminatedBreast Cancer | Breast Cancer Stage I | Breast Cancer Stage II | Breast Cancer Stage III | Breast Cancer Stage IIB | Breast Cancer Stage IIA | Breast Cancer Stage IIIA | Breast Cancer Stage IIIB | Breast Cancer Stage IIIcUnited States
-
University of Southern CaliforniaNational Cancer Institute (NCI)WithdrawnStage IV Breast Cancer | Stage II Breast Cancer | Stage IIIA Breast Cancer | Stage IIIB Breast Cancer | Triple-negative Breast Cancer | Stage IA Breast Cancer | Stage IB Breast Cancer | Stage IIIC Breast Cancer | Recurrent Breast Cancer
-
CelgeneCompletedBreast Cancer | Metastatic Breast Cancer | Stage IV Breast Cancer | Triple-negative Breast Cancer | Recurrent Breast Cancer | Breast Tumor | Cancer of the Breast | Triple-negative Metastatic Breast Cancer | Estrogen Receptor- Negative Breast Cancer | HER2- Negative Breast Cancer | Progesterone Receptor- Negative...United States, United Kingdom, Italy, Germany, Spain, Canada, Portugal, Australia, Austria, Greece, Brazil, France
-
University of Southern CaliforniaNational Cancer Institute (NCI)TerminatedHER2-positive Breast Cancer | Stage IV Breast Cancer | Stage II Breast Cancer | Stage IIIA Breast Cancer | Stage IIIB Breast Cancer | Stage IA Breast Cancer | Stage IB Breast Cancer | Stage IIIC Breast Cancer | Recurrent Breast CancerUnited States
-
University of WashingtonNational Cancer Institute (NCI)CompletedHER2-positive Breast Cancer | Stage II Breast Cancer | Stage IIIA Breast Cancer | Stage IA Breast Cancer | Stage IB Breast Cancer | Estrogen Receptor-negative Breast Cancer | Estrogen Receptor-positive Breast Cancer | Progesterone Receptor-negative Breast Cancer | Progesterone Receptor-positive Breast...United States
Clinical Trials on Levobupivacaine
-
Pontificia Universidad Catolica de ChileUnknown
-
University of PatrasCompletedPostoperative Pain | Morbid Obesity | Postoperative Bowel Function | Postoperative AmbulationGreece
-
Duzce UniversityCompletedPain, Postoperative | Cholecystectomy, LaparoscopicTurkey
-
Assiut UniversityCompletedPain, Postoperative | AnalgesiaEgypt
-
Balikesir UniversityCompleted
-
University Hospital, AntwerpCompletedSurgery | Hallux ValgusBelgium
-
Assiut UniversityCompletedLevobupivacaine | Post-tonsillectomy AnalgesiaEgypt
-
Kuopio University HospitalAdmescope LtdCompletedSurgery | Pain PostoperativeFinland
-
University Hospital, GhentCompleted
-
Mahidol UniversityCompletedDisease (or Disorder); Gynecological | Observation of Neuromuscular BlockThailand